A Phase 1 Study of Eribulin Mesylate, a Novel Microtubule Targeting Chemotherapeutic Agent in Children With Refractory or Recurrent Solid Tumors (Excluding CNS), Including Lymphomas
Phase of Trial: Phase I
Latest Information Update: 22 Jan 2019
Price : $35 *
At a glance
- Drugs Eribulin (Primary)
- Indications Solid tumours
- Focus Adverse reactions; Pharmacokinetics
- Acronyms BOLD 113
- Sponsors Eisai Inc
- 31 Jan 2018 Status changed from recruiting to completed.
- 31 Oct 2016 Planned number of patients changed from 20 to 23.
- 15 Sep 2016 Planned primary completion date changed from 1 Jul 2017 to 1 Nov 2016.